ClinicalTrials.gg
CompletedNCT07826065Updated Sep 23, 2026

Comparison of the Effects of Intermittent Fasting and Frequent Feeding Strategies on Weight Loss in Obese Women

An interventional study of 16:8 Time-Restricted Feeding and Exercise and Standart Diet and Exercise in Obesity & Overweight, sponsored by TC Erciyes University. Completed at 1 site in Turkey (Türkiye). Open to female participants aged 45 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by TC Erciyes University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled May 2025, registered Sep 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
45 Years to 65 Years
Sex
Female
01

Study summary

This study was conducted to compare the effects of a 12-week 16:8 Time-Restricted Feeding (Intermittent Fasting) + home-based exercise protocol with and a calorie-restricted Standard Diet (SD) + home-based exercise protocol on body composition, lipid profile, glycemic control, and liver function enzyme levels in obese women.

02

Conditions studied

  • Obesity & Overweight

Keywords

  • Intermittent Fasting
  • Time-Restricted Feeding
  • Obesity
  • Body Composition
  • ALT
  • Exercise
03

In context

Obesity

11,522 studies on the registry are indexed under Obesity; 2,033 are open to participants now.

This study's enrollment of 66 is close to the median of 67 across 9,006 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

TC Erciyes University is the lead sponsor of 349 studies on the registry; 74 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. between 30 and 40
  2. Female
  3. Agreeing to adhere to a calorie-restricted diet
  4. Agreeing to adhere to an exercise program

Exclusion criteria

Exclusion Criteria:

  1. Having cancer, diabetes, or thyroid disease
  2. Having received assistance with weight loss in the last 3 months
  3. Inability to adhere to calorie restriction
  4. Failure to adhere to an exercise program
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    Intermittent Fasting

    Other: 16:8 Time-Restricted Feeding and Exercise

  • Active comparator
    Standart Diet

    Other: Standart Diet and Exercise

  • No intervention
    Control Group

Interventions

  • Other16:8 Time-Restricted Feeding and Exercise

    Participants followed a 16:8 time-restricted feeding protocol (fasting for 16 hours and consuming all daily caloric intake within an 8-hour window) combined with a structured home-based exercise program for 12 weeks.

  • OtherStandart Diet and Exercise

    Participants followed a standard energy-restricted diet distributed across regular daily meals combined with a structured home-based exercise program for 12 weeks

06

What researchers measure

Primary outcomes

  1. Change in Fasting Blood Glucose

    Evaluation of changes in fasting blood glucose levels.

    Time frame: Baseline and 12 weeks

  2. Change in HOMA-IR Index

    Evaluation of changes in insulin resistance index.

    Time frame: Baseline and 12 weeks

  3. Change in Lipid Profile Parameters

    Evaluation of changes in serum total cholesterol, triglycerides, HDL, and LDL levels.

    Time frame: Baseline and 12 weeks

  4. Change in Serum ALT Level

    Evaluation of changes in alanine aminotransferase enzyme levels.

    Time frame: Baseline and 12 weeks

  5. Change in Serum AST Level

    Evaluation of changes in aspartate aminotransferase enzyme levels.

    Time frame: Baseline and 12 weeks

  6. Change in Body Mass Index (BMI)

    Evaluation of changes in body mass index calculated as weight in kilograms divided by height in meters squared (kg/m²).

    Time frame: Baseline and 12 weeks

  7. Change in Body Weight

    Evaluation of changes in body weight in kilograms.

    Time frame: Baseline and 12 weeks

  8. Change in Body Fat Percentage

    Evaluation of changes in body fat percentage assessed via Bioelectrical Impedance Analysis (BIA).

    Time frame: Baseline and 12 weeks

  9. Change in Total Cholesterol

    Evaluation of changes in serum total cholesterol levels (mg/dL).

    Time frame: Baseline and 12 weeks

  10. Change in Triglycerides

    Evaluation of changes in serum triglyceride levels (mg/dL).

    Time frame: Baseline and 12 weeks

  11. Change in HDL Cholesterol

    Evaluation of changes in high-density lipoprotein cholesterol levels (mg/dL).

    Time frame: Baseline and 12 weeks

  12. Change in LDL Cholesterol

    Evaluation of changes in low-density lipoprotein cholesterol levels (mg/dL).

    Time frame: Baseline and 12 weeks

07

Study locations

1 site
  • Erciyes University
    Kayseri, Kayseri 38100, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Jul 2026, 13 months.

Of 3,680 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 13 months is below that.

Counting every sponsor, half of 3,843 studies reached it within 22 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2026
First posted
Sep 17, 2026
StartActual
May 2, 2025
Primary completionActual
Jul 1, 2026
CompletionActual
Aug 20, 2026
Last update
Sep 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07826065
Responsible party
Alihan ILOGLU (PhD Candidate, TC Erciyes University) — Principal investigator
First posted
Sep 17, 2026
Start date
May 2, 2025
Primary completion
Jul 1, 2026
Completion
Aug 20, 2026
Last update
Sep 23, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion